DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07360457

Not yet recruiting

GLP1 Analogues and the Risk of Osteoarthritis

Association of GLP1 Analogues and SGLT2 Inhibitors With the Risk of Osteoarthritis in Type 2 Diabetic Patients

Asset

GLP-1 / incretin class catch-all

Listed sites

0

Recruiting sites

—

Enrollment

390

estimated

Study population

Osteoarthritis, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•WOMAC function

Identifiers

Registered as

NCT IDNCT07360457
Org study IDGLP1

Timeline

Milestones

Study first posted2026-01-22actual
Last update posted2026-01-22actual
Study start2026-02-01estimated
Primary completion2026-12-01estimated
Study completion2027-03-01estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

OsteoarthritisType 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

130 T2DM patients will be admitted in each group Group 1 : T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care Group 2: T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care Group 3: T2DM patients receiving only standard of care

Inclusion criteria

•Adults aged above 50 years old with a previous diagnosis of T2DM according to ADA 2025, who have been on either SGLT2 inhibitors or GLP-1 analogs for at least one year.

Exclusion criteria

•individuals with Type 1 Diabetes Mellitus
•non-diabetic individuals
•those taking prandial insulin
•patients with arthritis without osteoarthritis,
•those taking other medications contraindicated with study medications,
•pregnant or breastfeeding females
•those allergic to active ingredients,
•those using corticosteroids, Autoimmune disease patients or patients receiving immunotherapies, monoclonal antibody targeting TNF-α or IL-6.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
1
Other clinical outcomes
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

VAS pain score

Time frame:at Day 1

descriptive, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

WOMAC score

Time frame:at Day 1

WOMAC function

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.